FULC
Fulcrum Therapeutics, Inc. NASDAQ Listed Jul 18, 2019$3.77
After hrs
$3.77
+0.00%
Mkt Cap $204.0M
52w Low $2.83
7.3% of range
52w High $15.74
50d MA $6.24
200d MA $8.60
P/E (TTM)
—
EV/EBITDA
—
P/B
0.7x
Debt/Equity
0.0x
ROE
-22.8%
P/FCF
-3.9x
RSI (14)
18.80
ATR (14)
$0.27
Beta
3.27
50d MA
$6.24
200d MA
$8.60
Avg Volume
3.2M
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
26 Landsdowne Street · Cambridge, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | TNS | -0.31 | -0.25 | +19.4% | 7.72 | +0.0% | -3.6% | -3.9% | -0.3% | +3.2% | -4.6% | — |
| Feb 24, 2026 | TNS | -0.31 | -0.31 | +0.0% | 8.58 | -2.6% | +4.7% | -2.8% | -4.0% | -6.8% | +0.8% | — |
| Oct 29, 2025 | TNS | -0.29 | -0.31 | -6.9% | 9.36 | +1.6% | -8.1% | +1.7% | +3.1% | -7.2% | -6.0% | — |
| Jul 29, 2025 | TNS | -0.29 | -0.28 | +3.4% | 7.59 | +0.1% | -9.1% | -2.5% | +1.5% | +1.9% | -1.1% | — |
| May 1, 2025 | TNS | -0.29 | -0.28 | +3.4% | 4.38 | +0.7% | +28.3% | +2.0% | -6.6% | -5.2% | +6.7% | — |
| Feb 25, 2025 | TNS | -0.28 | -0.31 | -10.7% | 3.70 | -0.8% | -10.3% | +1.5% | +6.5% | -9.7% | +0.9% | — |
| Nov 13, 2024 | TNS | -0.40 | -0.35 | +12.5% | 3.56 | +0.3% | -6.7% | -9.3% | +0.7% | -0.7% | -0.7% | — |
| Jul 31, 2024 | TNS | 0.01 | 0.87 | +7060.9% | 9.28 | +1.5% | -2.9% | +6.0% | -11.4% | +4.8% | -6.5% | — |
| May 13, 2024 | TNS | -0.44 | -0.43 | +2.3% | 7.35 | +7.2% | +7.6% | +4.3% | -5.5% | -3.2% | +2.0% | — |
| Feb 27, 2024 | TNS | -0.44 | -0.40 | +9.1% | 10.18 | +0.9% | +1.4% | -1.1% | +7.6% | +3.1% | -3.3% | — |
| Nov 7, 2023 | TNS | -0.44 | -0.39 | +11.4% | 4.29 | -0.2% | -2.8% | -18.7% | +3.2% | -0.9% | +13.3% | — |
| Aug 3, 2023 | TNS | -0.44 | -0.38 | +13.6% | 3.85 | +0.3% | +2.6% | +1.5% | +0.5% | -1.5% | +7.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 3 | JP Morgan | Downgrade | Overweight → Underweight | — | $3.14 | $3.11 | -1.0% | +2.5% | +4.7% | +9.5% | -6.8% | +2.3% |
| Jun 2 | Truist | Downgrade | Buy → Hold | $4 | $6.42 | $3.11 | -51.6% | -51.1% | +2.5% | +4.7% | +9.5% | -6.8% |
| Jun 2 | H.C. Wainwright | Downgrade | Buy → Neutral | $3 | $6.42 | $3.11 | -51.6% | -51.1% | +2.5% | +4.7% | +9.5% | -6.8% |
| Jun 2 | Leerink Partners | Downgrade | Outperform → Market Perform | $4 | $6.42 | $3.11 | -51.6% | -51.1% | +2.5% | +4.7% | +9.5% | -6.8% |
| Jun 2 | Piper Sandler | Downgrade | Overweight → Neutral | $3 | $6.42 | $3.11 | -51.6% | -51.1% | +2.5% | +4.7% | +9.5% | -6.8% |
| Jun 2 | Stifel | Downgrade | Buy → Hold | $3 | $6.42 | $3.11 | -51.6% | -51.1% | +2.5% | +4.7% | +9.5% | -6.8% |
| Dec 11 | Truist | Maintains | Buy → Buy | — | $13.80 | $13.55 | -1.8% | -7.2% | +1.6% | -0.6% | -3.3% | -3.4% |
| Dec 9 | BofA Securities | Maintains | Underperform → Underperform | — | $12.99 | $12.72 | -2.1% | +12.4% | -5.5% | -7.2% | +1.6% | -0.6% |
| Dec 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $8.90 | $12.96 | +45.6% | +46.0% | +12.4% | -5.5% | -7.2% | +1.6% |
| Dec 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.90 | $12.96 | +45.6% | +46.0% | +12.4% | -5.5% | -7.2% | +1.6% |
| Dec 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.90 | $12.96 | +45.6% | +46.0% | +12.4% | -5.5% | -7.2% | +1.6% |
| Dec 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.90 | $12.96 | +45.6% | +46.0% | +12.4% | -5.5% | -7.2% | +1.6% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.29 | $11.73 | +3.9% | +4.0% | -1.7% | -1.9% | -3.4% | -9.8% |
| Oct 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $9.36 | $9.51 | +1.6% | -8.1% | +1.7% | +3.1% | -7.2% | -6.0% |
| Oct 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.36 | $9.51 | +1.6% | -8.1% | +1.7% | +3.1% | -7.2% | -6.0% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.99 | $9.12 | +1.4% | +2.6% | +5.2% | -6.8% | -1.0% | +3.0% |
| Jul 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $7.59 | $7.60 | +0.1% | -9.1% | -2.5% | +1.5% | +1.9% | -1.1% |
| Jul 29 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $7.81 | $7.66 | -1.9% | -2.8% | -9.1% | -2.5% | +1.5% | +1.9% |
| May 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.90 | $7.11 | +3.0% | +2.5% | -2.7% | +1.2% | +1.1% | -0.1% |
| May 23 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $6.12 | $6.82 | +11.4% | +5.2% | -1.4% | +8.7% | +2.5% | -2.7% |
| May 15 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $5.63 | $5.99 | +6.4% | +17.2% | +4.2% | +0.7% | -6.1% | -4.0% |
| Feb 26 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.70 | $3.67 | -0.8% | -10.3% | +1.5% | +6.5% | -9.7% | +0.9% |
| Nov 14 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $3.56 | $3.57 | +0.3% | -6.7% | -9.3% | +0.7% | -0.7% | -0.7% |
| Nov 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.56 | $3.57 | +0.3% | -6.7% | -9.3% | +0.7% | -0.7% | -0.7% |
| Sep 13 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $3.44 | $3.44 | +0.0% | -7.6% | +0.0% | +9.7% | -1.4% | +0.3% |
| Sep 13 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $3.44 | $3.44 | +0.0% | -7.6% | +0.0% | +9.7% | -1.4% | +0.3% |
| Sep 12 | BofA Securities | Downgrade | Neutral → Underperform | — | $8.85 | $2.94 | -66.8% | -61.1% | -7.6% | +0.0% | +9.7% | -1.4% |
| Sep 12 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $8.85 | $2.94 | -66.8% | -61.1% | -7.6% | +0.0% | +9.7% | -1.4% |
| Sep 12 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $8.85 | $2.94 | -66.8% | -61.1% | -7.6% | +0.0% | +9.7% | -1.4% |
| Sep 12 | Stifel | Downgrade | Buy → Hold | — | $8.85 | $2.94 | -66.8% | -61.1% | -7.6% | +0.0% | +9.7% | -1.4% |
| Sep 9 | BofA Securities | Upgrade | Underperform → Neutral | — | $8.54 | $8.90 | +4.2% | +1.1% | -2.3% | +5.0% | -61.1% | -7.6% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.28 | $9.42 | +1.5% | -2.9% | +6.0% | -11.4% | +4.8% | -6.5% |
| Jul 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.53 | $6.58 | +0.8% | +8.6% | +10.0% | +2.7% | +5.5% | +2.5% |
| May 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.35 | $7.88 | +7.2% | +7.6% | +4.3% | -5.5% | -3.2% | +2.0% |
| May 14 | Goldman Sachs | Upgrade | Neutral → Buy | — | $7.35 | $7.88 | +7.2% | +7.6% | +4.3% | -5.5% | -3.2% | +2.0% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.35 | $7.88 | +7.2% | +7.6% | +4.3% | -5.5% | -3.2% | +2.0% |
| May 13 | Goldman Sachs | Upgrade | Neutral → Buy | — | $7.47 | $8.35 | +11.8% | -1.6% | +7.6% | +4.3% | -5.5% | -3.2% |
| Feb 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.18 | $10.27 | +0.9% | +1.4% | -1.1% | +7.6% | +3.1% | -3.3% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.18 | $10.27 | +0.9% | +1.4% | -1.1% | +7.6% | +3.1% | -3.3% |
| Jan 26 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.00 | $7.04 | +0.6% | -0.7% | +7.8% | -3.3% | -0.3% | +11.1% |
| Jan 25 | Goldman Sachs | Maintains | Neutral → Neutral | — | $6.70 | $6.80 | +1.5% | +4.5% | -0.7% | +7.8% | -3.3% | -0.3% |
| Aug 23 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $5.43 | $5.60 | +3.1% | +12.0% | -11.0% | +1.7% | +5.1% | -3.3% |
| Aug 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.92 | $5.28 | +34.7% | +38.5% | +12.0% | -11.0% | +1.7% | +5.1% |
| Aug 22 | Stifel | Upgrade | Hold → Buy | — | $3.92 | $5.28 | +34.7% | +38.5% | +12.0% | -11.0% | +1.7% | +5.1% |
| Aug 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.85 | $3.86 | +0.3% | +2.6% | +1.5% | +0.5% | -1.5% | +7.8% |
| May 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.64 | $3.62 | -0.5% | +4.4% | -3.7% | -10.4% | -0.9% | -5.5% |
| May 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.64 | $3.62 | -0.5% | +4.4% | -3.7% | -10.4% | -0.9% | -5.5% |
| May 5 | Goldman Sachs | Maintains | Neutral → Neutral | — | $2.74 | $2.80 | +2.2% | +3.6% | +8.5% | +6.2% | +0.0% | -2.8% |
| May 4 | Goldman Sachs | Downgrade | Buy → Neutral | — | $2.93 | $2.70 | -7.8% | -6.5% | +3.6% | +8.5% | +6.2% | +0.0% |
| Mar 13 | Goldman Sachs | Maintains | Buy → Buy | — | $4.51 | $4.43 | -1.8% | -0.2% | -11.8% | -4.3% | -3.2% | -6.2% |
No insider trades available.
8-K · 5.02
!!! Very High
Fulcrum Therapeutics, Inc. -- 8-K 5.02: Executive Change
Fulcrum Therapeutics appointed Josh Lehrer to its board as a Class III director, potentially signaling fresh strategic input and expanded governance oversight for the therapeutic company.
Apr 27
8-K
Fulcrum Therapeutics, Inc. -- 8-K Filing
Fulcrum Therapeutics reported positive 12-week PIONEER trial data for pociredir in its 20 mg cohort, supporting the drug candidate's potential in treating genetically defined rare diseases.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Braidwell Lp | 3,061,222 | $35M | Added | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 2,692,948 | $21M | New | Mar 2026 |
| 3 | Aberdeen Group Plc | 2,211,953 | $17M | Added | Mar 2026 |
| 4 | Point72 Asset Management | 2,074,855 | $16M | Reduced | Mar 2026 |
| 5 | Gsk Plc | 1,785,714 | $14M | — | Mar 2026 |
| 6 | Jones Hill Capital Lp | 1,771,926 | $14M | New | Mar 2026 |
| 7 | D.e. Shaw & Co | 1,623,281 | $12M | Reduced | Mar 2026 |
| 8 | Alyeska Investment Group, L.p. | 1,328,449 | $10M | New | Mar 2026 |
| 9 | Citadel Advisors Llc | 1,292,486 | $10M | Added | Mar 2026 |
| 10 | Assenagon Asset Management S.a. | 1,193,873 | $9M | New | Mar 2026 |
| 11 | Qube Research & Technologies Ltd | 974,739 | $7M | Added | Mar 2026 |
| 12 | Connor, Clark & Lunn Investment Management Ltd. | 582,377 | $7M | Added | Dec 2025 |
| 13 | Jane Street Group, Llc | 493,750 | $6M | Added | Dec 2025 |
| 14 | Acadian Asset Management Llc | 727,315 | $6M | Reduced | Mar 2026 |
| 15 | Vanguard Portfolio Management Llc | 599,379 | $5M | New | Mar 2026 |
| 16 | Silverarc Capital Management, Llc | 394,650 | $4M | New | Dec 2025 |
| 17 | Aqr Capital Management Llc | 543,165 | $4M | Added | Mar 2026 |
| 18 | Morgan Stanley | 331,246 | $4M | Reduced | Dec 2025 |
| 19 | Northern Trust Corp | 472,985 | $4M | Reduced | Mar 2026 |
| 20 | Millennium Management | 356,471 | $3M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$204.0M
Enterprise Value
-$113.9M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.01x
P/B
0.68x
P/S
—
P/FCF
-3.88x
EV/EBITDA
—
Shares Out
63.4M
Financials (TTM)
Revenue
$0
Net Income
-$76.1M
EBITDA
-$74.7M
Free Cash Flow
-$60.4M
Op Cash Flow
-$60.1M
EPS Basic
$-1.18
EPS Diluted
$-1.15
EPS Forward
$-1.21
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$366.3M
Total Liab.
$17.3M
Total Equity
$349.0M
Cash
$352.3M
LT Debt
$4.0M
Book Value/Sh
$5.51
Debt/Equity
0.02x
Current Ratio
27.40
Quick Ratio
27.40
Returns & Growth
ROE
-22.8%
ROA
-21.9%
ROIC
-23.8%
Rev Growth YoY
-100.0%
EPS Growth YoY
-637.5%
Price Returns
2W
-2.7%
1M
-2.9%
3M
-17.4%
6M
-36.7%
12M
+0.6%
Technicals
52W High
$15.74
52W Low
$2.83
50d MA
$6.24
200d MA
$8.60
RSI (14)
18.80
ATR (14)
$0.27
Beta
3.27
Avg Volume
3.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$20.67
High
$25.00
Low
$10.00
Median
$23.50
Data updated apr 25, 2026 10:22am
· Source: financialmodelingprep.com